Muir is a consultant for, is on the speakers' bureau of, and received grants from Merck. He received grants from Valeant. He is also a consultant for and received grants from Zynogenetics. Dr. Poordad is a consultant for and received grants from Valeant. Dr. Shiffman advises and received grants from
Histologic outcomes in hepatitis C–infected patients with varying degrees of virologic response to interferon-based treatments
✍ Scribed by Paul J. Pockros; Fayez M. Hamzeh; Paul Martin; Ellen Lentz; Xiaolei Zhou; Sugantha Govindarajan; Anna S. Lok
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 165 KB
- Volume
- 52
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
✦ Synopsis
is a consultant for, is on the speakers' bureau of, and received grants from Roche, Gilead, and Bristol-Myers Squibb. Dr. Pockros is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche and Bristol-Myers Squibb. He is also a consultant for, advises, and received grants from Vertex. Dr. Govindarajan received grants from Roche. Dr. Lok advises and received grants from Roche. She also received grants from Schering-Plough.
📜 SIMILAR VOLUMES
## Abstract Hepatitis C virus (HCV) infection remains common among hemodialysis patients and its occurrence is related mainly to nosocomial spread. Although dialysis patients with HCV infection respond well to interferon‐based therapy, relapse is frequent. This study aimed at a selected group of he
## Abstract Patients with high viral load (≥1.0 × 10^5^ IU/ml) of hepatitis C virus (HCV) genotype 1b do not achieve high sustained virological response rates to interferon (IFN)/ribavirin combination therapy. Previous studies suggested that pretreatment amino acid (aa) substitution patterns in the
## Abstract Several factors, including metabolic profile, are predictive of response to standard antiviral therapy in patients with chronic hepatitis C. In a retrospective study, it was investigated whether uric acid, involved in metabolic syndrome, could be included. A total of 153 patients (56.2%
biochemical and histological improvement. 3,4 Several factors Hepatitis C virus (HCV) genotype 1b and high precan predict a poor response to interferon therapy, e.g., high treatment virus load are predictive factors of poor repretreatment virus load, genotype 1b, advanced histological sponse to inte